Stand Up To Cancer initiates ten clinical trial projects for oncology

16th October 2017 (Last Updated October 16th, 2017 00:00)

Entertainment Industry Foundation's (EIF) Stand Up To Cancer (SU2C) initiative has launched ten SU2C Catalyst clinical trial projects for the treatment of different types of the disease.

Stand Up To Cancer initiates ten clinical trial projects for oncology
Histopathogic image of pancreatic adenocarcinoma. Credit: KGH.

Entertainment Industry Foundation's (EIF) Stand Up To Cancer (SU2C) initiative has launched ten SU2C Catalyst clinical trial projects for the treatment of different types of the disease.

The projects will involve researchers from more than 30 organisations for performing correlated translational research to obtain better insights into the efficacy of cancer treatments.

Additionally, the projects will investigate new uses of medicines from three SU2C Catalyst Charter Supporters and six additional pharmaceutical firms.

The Charter Supporters, Merck, Bristol-Myers Squibb and Genentech, are set to provide the grants required to support the trials, along with their new pharmaceutical compounds and approved agents for evaluation as monotherapy or combination treatments by the academic cancer research community.

AbbVie, Astex Pharmaceuticals, Iovance Biotherapeutics, Mirati Therapeutics, Prometheus Laboratories and TESARO are also providing compounds or financial support for the trials.

SU2C president and CEO Sung Poblete said: “This unique industry/academic collaboration has reduced the time for SU2C to get clinical trials started by more than 75% while bringing significant scientific rigor to the selection and oversight of the projects.

“SU2C actively manages these grants to minimise delays and support the achievement of key milestones.”

The ten inaugural projects will target various oncology types such as breast, lung, melanoma, multiple myeloma, ovarian, pancreatic, hypermutant paediatric, sarcoma and urothelial.

During the trials, supplied compounds will be assessed in combination with other medicines, devices, therapies or standard-of-care treatments.

In addition to the efficacy of the combinations, the research will also study the reason for their action.


Image: Histopathogic image of pancreatic adenocarcinoma. Photo: courtesy of KGH.